super-resolution-microscopy
(3)
Sanavia Oncology Inc.
Sanavia Oncology is a New York-based biotech company developing next-generation cancer immunotherapies for patients who don't benefit from existing treatments. Its proprietary platform pairs high-throughput sequencing, single-molecule super-resolution microscopy, 3D protein modeling and artificial intelligence to discover novel, clinically relevant cancer-specific epitopes in drug-resistant tumors, then generates antibodies with atomic-level specificity to those targets. The company is building antibody drug conjugates (ADCs), bispecific T cell engagers (TCEs) and CAR-T therapies - led by its SANA-01 ADC - and is backed by Two Bear Capital.
Paul Scagnetti
Paul Scagnetti is the CEO of ONI (Oxford Nanoimaging), the Oxford spin-out behind the Nanoimager, the first desktop super-resolution microscope to see single molecules at 20 nanometer resolution. A mechanical engineer with a PhD from MIT and 25+ years in life sciences and instruments, he left a job he loved at Illumina in February 2023 to bet that making Nobel-grade imaging simple enough for any lab would change drug discovery. In January 2025 he shipped the Aplo Scope, which he calls the biggest launch in ONI's history.
ONI
ONI (Oxford Nanoimaging) is an Oxford University spinout that shrank the super-resolution microscope from a room-sized, six-figure instrument into a desktop box the size of a sheet of A4 paper. Its flagship Nanoimager resolves single molecules down to 20 nm and pairs with the cloud-based CODI platform for analysis and collaboration, opening single-molecule science to labs studying everything from extracellular vesicles to lipid nanoparticles and cancer.